Previous close | 15.15 |
Open | 11.95 |
Bid | 11.45 |
Ask | 11.65 |
Strike | 155.00 |
Expiry date | 2024-10-18 |
Day's range | 11.05 - 12.20 |
Contract range | N/A |
Volume | |
Open interest | 852 |
Data from a late-stage study shows that Moderna's (MRNA) next-generation COVID-19 vaccine achieved non-inferior vaccine efficacy against COVID-19 when compared with its previously approved bivalent COVID-19 vaccine.
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
Moderna revealed its combination flu/COVID vaccine performed better than the two shots independently.